Drug Could Make Melanoma More Vulnerable to Chemo
...at the Society of Surgical Oncology annual meeting in Phoenix, and have been accepted for publication in the journal Cancer . The study was funded by adherex Technologies, which is developing ADH-1. "These early results are very exciting, because metastatic melanoma is one of the most deadly cancers and ...Drug combination may be effective against deadly melanoma, pilot study shows
...ociety of Surgical Oncology annual meeting, and results of the study have been accepted for publication in the journal Cancer. The study was funded by adherex Technologies, the company developing the compound that was tested in combination with chemotherapy, the United States Department of Veterans Affairs, ...Combination therapy packs 1-2 punch against melanoma
...d their findings June 1 in a poster discussion session at the American Society of Clinical Oncology annual meeting in Chicago. The study was funded by adherex Technologies, the company developing the compound that was tested in combination with chemotherapy. Sixteen patients received the therapy as part o...Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma
... came from the United States Department of Veterans Affairs, the Duke Institute for Genome Sciences & Policy, the Duke Comprehensive Cancer Center and adherex Technologies, the company developing the compound that was tested in combination with chemotherapy. After being implanted with melanoma tumors, rat...OHSU turns innovations into commercial opportunities at record pace
...23 million from $719,800 the previous year. The market value of equity OHSU owns in six startups whose shares are publicly traded Novacea, Inc.; adherex Technologies Inc.; Neurocrine Biosciences, Inc.; Orexigen Therapeutics, Inc.; StemCells, Inc. and Fonix Corporation reached $2.25 million at the end ...